https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-08-01 / Anticancer Res 2009 Aug;29(8):3465-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-08-01 / Anticancer Res 2009 Aug;29(8):3465-72009-08-01 00:00:002009-08-01 00:00:00Serum and tissue selenium levels in gastric cancer patients and correlation with CEA
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-18 / Cancer Immunol. Immunother. 2010 Jan;59(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-18 / Cancer Immunol. Immunother. 2010 Jan;59(1):1-112009-07-18 00:00:002019-02-15 08:44:12Killer dendritic cells and their potential for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-08 / Cochrane Database Syst Rev 2009 Jul;(3):CD006269
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-08 / Cochrane Database Syst Rev 2009 Jul;(3):CD0062692009-07-08 00:00:002019-02-15 08:38:00Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-07 / Clin. Cancer Res. 2009 Jul;15(14):4612-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-07 / Clin. Cancer Res. 2009 Jul;15(14):4612-212009-07-07 00:00:002019-02-15 08:44:17Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-01 / J. Immunother. 2009 Jul-Aug;32(6):638-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-01 / J. Immunother. 2009 Jul-Aug;32(6):638-542009-07-01 00:00:002019-02-15 08:44:18Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-01 / J. Intern. Med. 2009 Jul;266(1):99-113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-01 / J. Intern. Med. 2009 Jul;266(1):99-1132009-07-01 00:00:002019-02-15 08:53:36Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-15 / J. Infect. Dis. 2009 Jun;199(12):1862-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-15 / J. Infect. Dis. 2009 Jun;199(12):1862-712009-06-15 00:00:002019-02-15 08:48:00Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-15 / Prostate 2009 Jun;69(9):938-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-15 / Prostate 2009 Jun;69(9):938-482009-06-15 00:00:002019-02-15 08:53:14Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-10 / J. Virol. 2009 Aug;83(16):8108-212009-06-10 00:00:002021-11-15 17:01:25Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-82009-06-01 00:00:002019-02-15 09:17:33Hyperthermia as an immunotherapy strategy for cancer
